# Phase I/II Trial of Bevacizumab, Pemetrexed and Erlotinib in Elderly Patients With Non-Small Cell Lung Cancer

> **NCT00351039** · PHASE1,PHASE2 · TERMINATED · sponsor: **H. Lee Moffitt Cancer Center and Research Institute** · enrollment: 8 (actual)

## Conditions studied

- Non-Small Cell Lung Cancer

## Interventions

- **DRUG:** Bevacizumab
- **DRUG:** Erlotinib
- **DRUG:** Pemetrexed

## Key facts

- **NCT ID:** NCT00351039
- **Lead sponsor:** H. Lee Moffitt Cancer Center and Research Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2006-07
- **Primary completion:** 2008-09
- **Final completion:** 2008-09
- **Target enrollment:** 8 (ACTUAL)
- **Why stopped:** slow accrual
- **Last updated:** 2017-03-23

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00351039

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00351039, "Phase I/II Trial of Bevacizumab, Pemetrexed and Erlotinib in Elderly Patients With Non-Small Cell Lung Cancer". Retrieved via AI Analytics 2026-09-09 from https://api.ai-analytics.org/clinical/NCT00351039. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*